Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model.

Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model.

Item
http://www.wikidata.org/entity/Q36825820
Are there ways to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease?Vascular calcification: When should we interfere in chronic kidney disease patients and how?Reduction of costs for anemia-management drugs associated with the use of ferric citrateFerric citrate.Iron-based phosphate binders: do they offer advantages over currently available phosphate binders?Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data.Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation ModelComment on: "Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Mode".Is It Too Much of a Good Thing? A New Era in Phosphate Binder Therapy in ESRD.
P2860

Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model.

Item
http://www.wikidata.org/entity/Q36825820
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Reduced use of erythropoiesis- ...... anaged care cost-offset model.
@en
type
label
Reduced use of erythropoiesis- ...... anaged care cost-offset model.
@en
prefLabel
Reduced use of erythropoiesis- ...... anaged care cost-offset model.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P478
P577
P698
P932
P356
P1433
P1476
Reduced use of erythropoiesis- ...... anaged care cost-offset model.
@en
P2093
P2860
P304
P31
P356
P407
P478
P577
P698
P932